Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)

Correlation of Anti-CCP With Disease Activity and Its Impact on Biological Response in PsA in Iraqi Patients

This study is to evaluate the local data in Iraqi patients with psoriatic arthritis on Enbrel treatment with positive Anti-Cyclic Citrullinated Peptide using data from the Rheumatologist in Baghdad Teaching Hospital registry.

Inclusion Criteria:

• Diagnosed PsA patients.
• ≥18 years of age
• Have not received previous biological treatment

Exclusion Criteria:

• Previous use of other biological treatments.
• Etanercept use for less than 1 year duration.